Tamai, I., et al. 2000. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273:251-260.
Schuster, V.L. 1998. Molecular mechanisms of prostaglandin transport. Annu. Rev. Physiol. 60:221-242.
Topper, J.N., et al. 1998. Human prostaglandin transporter gene (hPGT) is regulated by fluid mechanical stimuli in cultured endothelial cells and expressed in vascular endothelium in vivo. Circulation. 98:2396-2403.
Narumiya, S., and Fukushima, M. 1986. Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. J. Pharmacol. Exp. Ther. 239:500-505.
Narumiya, S., Ohno, K., Fujiwara, M., and Fukushima, M. 1986. Site and mechanism of growth inhibition by prostaglandins. II. Temperature-dependent transfer of a cyclopentenone prostaglandin to nuclei. J. Pharmacol. Exp. Ther. 239:506-511.
Hayaishi, O. 2000. Molecular mechanisms of sleep-wake regulation: a role of prostaglandin D2. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 355:275-280.
Pratico, D., Cheng, Y., and FitzGerald, G.A. 2000. TP or not TP: primary mediators in a close run off? Arterioscler. Thromb. Vasc. Biol. 20:1695-1698.
Austin, S., and FitzGerald, G.A. 1999. Not a mouse stirring: deletion of the EP2 and loves labor lost. J. Clin. Invest. 103:1481-1482.
Suzawa, T., et al. 2000. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 141:1554-1559.
Ruel, R., et al. 1999. New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor. Bioorg. Med. Chem. Lett. 9:2699-2704.
Wright, D.H., Metters, K.M., Abramovitz, M., and Ford-Hutchinson, A.W. 1998. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br. J. Pharmacol. 123:1317-1324.
Patrono, C., et al. 2001. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 119:39S-63S.
FitzGerald, G.A., and Patrono, C. 2001. The Coxibs: selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. In press.
Catella-Lawson, F., et al. 1999. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289:735-741.
Topper, J.N., Cai, J., Falb, D., and Gimbrone, M.A., Jr. 1996. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively upregulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA. 93:10417-10422.
Kliewer, S.A., et al. 1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:813-819.
Devchand, P.R., et al. 1996. The PPARα-leukotriene B4 pathway to inflammation control. Nature. 384:39-43.
Forman, B.M., Chen, J., and Evans, R.M. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ Proc. Natl. Acad. Sci. USA. 94:4312-4317.
Fitzpatrick, F.A., and Wynalda, M.A. 1983. Albumin-catalyzed metabolism of prostanglandin D2. Identification of products formed in vitro. J. Biol. Chem. 258:11713-11718.
Kikawa, Y., Narumiya, S., Fukushima, M., Wakatsuka, H., and Hayaishi, O. 1984. 9-Deoxy-Δ, Δ12-13,14-dihydro-prostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma. Proc. Natl. Acad. Sci. USA. 81:1317-1321.
Hirata, Y., et al. 1988. Occurrence of 9-deoxy-Δ 9, Δ 12-13,14-dihydroxy-prostaglandin D2 in human urine. J. Biol. Chem. 263:16619-16625.
Maxey, K.M., Hessler, E., MacDonald, J., and Hitchingham, L. 2000. The nature and composition of 15-deoxy-Δ 12,14PGJ2. Prostaglandins Other Lipid Mediat. 62:15-21.
FitzGerald, G.A., Brash, A.R., Falardeau, P., and Oates, J.A. 1981. Estimated rate of prostacyclin secretion into the circulation of normal man. J. Clin. Invest. 68:1272-1275.
Patrono, C., et al. 1986. Estimated rate of thromboxane secretion into the circulation of normal man. J. Clin. Invest. 77:590-594.
Kliewer, S.A., et al. 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA. 94:4318-4323.
Straus, D.S., et al. 2000. 15-deoxy-Δ 12,14-prostaglandin J2 inhibits multiple steps in the NF-κ B signaling pathway. Proc. Natl. Acad. Sci. USA. 97:4844-4849.
Rocote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-γ is a negative regulator of macrophage activation. Nature. 391:79-82.
Jiang, C., Ting, A.T., and Seed, B. 1998. PPARγ agonists inhibit production of monocyte inflammation cytokines. Nature. 391:82-86.
Rossi, A., et al. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkB kinase. Nature. 403:103-108.
Gupta, R.A., et al. 2000. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc. Natl. Acad. Sci. USA. 97:13275-13280.